Catamaran Bio
Maina is a partner with Sofinnova Partners. Maina joined the firm in 2018 and has a long track record as a successful healthcare investor. Prior to joining Sofinnova Partners, she was Director of Healthcare Investment at Touchstone Innovations (formerly Imperial Innovations) in London (UK), where she led or co-led investments in the UK. Previously, she worked in the R&D teams of several UK and US biotech companies, including Celltech, Oxford Glyco Sciences, Chimeric Therapies and GeneMedicine. Maina holds a BS from the University of Texas at Austin and an MBA from the Imperial Business School. Maina’s current investments include Sitryx Therapeutics, Cincor, and Enyo Pharma.
This person is not in the org chart
This person is not in any offices
Catamaran Bio
Catamaran Bio is a newly-formed biotechnology company funded by SV Health Investors. Catamaran is developing transformative off-the-shelf CAR-NK cell therapies.